All News
Risankizumab for Active Psoriatic Arthritis
The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.
Read Article
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Read Article
@benjaminsutu @RheumNow Always steroids first, we learned that the hard way in GUSTO - but yeah, probably something after that, and TCZ is our only b/tsDMARD choice... for the time being
(at #ACR21 - mavrilimumab, baricitinib, secukinumab...)
David Liew drdavidliew ( View Tweet)
Dr. Petri noted that 1 week off of immunosuppressants is adequate for most lupus patients to mount a response. She avoided RTX during the pandemic. In pts who have had inadequate response to 2 or 3 doses of mRNA, she switches them to J&J. #ACR21 #COVI19 CH @rheumnow https://t.co/qNjmx9uTLF
TheDaoIndex KDAO2011 ( View Tweet)
TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed to TNFi reported in the CARRA registry w/ incidence rate the highest on children receiving adalimumab.
#Abst0241 @RheumNow #ACR2021 https://t.co/uXOwV2RlGu https://t.co/8f8mvVUkV2
Aurelie Najm AurelieRheumo ( View Tweet)
Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
Dr. Antoni Chan synovialjoints ( View Tweet)
HSS Study of 136 SLE flares post-vax:
👉100 (74%) w/expected AE (headache/myalgias)
👉11 (8.1%) pts with SLE flare
👉Majority of flares were mild-mod & occurred w/in 1 week of vaccination
👉Most resolved w/in 7 days.
Abst#0896 #ACR21 @rheumnow
https://t.co/e6AP8PPRH2
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Katie Liao presented an observational study comparing SLE pts who were Ro neg (n=208) vs Ro pos (n=185).
More of the (+)Ro pts had:
⬆️Adjusted mean SLEDIA >4
⬆️Proteinuria
⬆️Neutropenia,+RF, +dsDNA, and low C3 or C4
⬆️Discoid or malar rash
#ACR21 Abst#0323 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Fatigue fills us with dread: common, big issue, no proven meds, non-pharm Rx hard to access.
Pragmatic RCT in UK, inflamm rheum dx:
usual care v CBT v exercise program
(all remote delivery)
Clinically meaningful benefit - now how to access?
LIFT study #ACR21 ABST0462 @RheumNow https://t.co/XsSCzkbcCd
David Liew drdavidliew ( View Tweet)
@JointMD shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. @RheumNow #acr21 https://t.co/mVw05iFPhF
TheDaoIndex KDAO2011 ( View Tweet)
Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below.
https://t.co/MalO30jgo1
Or visit our YouTube channel-RheumNow.
https://t.co/nBUk64XBjU https://t.co/pYEFOM1Q2g
Dr. John Cush RheumNow ( View Tweet)
Distinguishing between #preeclampsia and #lupus nephritis flare in 🤰 #SLE patients is very important because management is different. #rheumatology #medtwitter https://t.co/Dc9ohJQ75L
sheila RHEUMarampa ( View Tweet)
Blurred line btwn RA, preRA & RA prevention which makes interpretation of RCTs problematic. I’ve learned that if pt has RA not meeting criteria, some Rx ⬇️chance of RA over time-MTX, now #Abatacept but was it RA anyway AND what happens when you stop Rx? #ACR21 @RheumNow abst#0505 https://t.co/HwivsITvCQ
Janet Pope Janetbirdope ( View Tweet)
#ACR21 #Aging #CommunityHub @UnaMakris @SattuiSEMD @KWyshamMD
Very engaging discussion on the 5 Ms of aging + how they interconnect:
👉🏻multimorbidity (⬆️ risk)
👉🏻meds (poly pharmacy)
👉🏻mentation (cognitive impairment)
👉🏻mobility and disability
👉🏻what matters most <to patient> https://t.co/mZpk3qQFgz
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine:
RA vs AAV/IIM
Higher IgG
Longer time-to-RTX
Lower RTX courses Number.
Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0336 ANA is not a great test for #lupus diagnosis. Multianalyte Assay Panel with Cell-Bound Complement Activation Products could improve diagnosis (OR 6.3) and Drug Initiation (OR 2.8). Can we speed up implementation to clinic? #RheumNow https://t.co/jLcAtD7FaY https://t.co/YmLwmVWp6k
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The #Lupus Faculty @RheumNow is proud to share our latest video about learning points from a jam-packed day at #ACR21 https://t.co/LRyuYyHlhi @KDAO2011 @Janetbirdope @bella_mehta @_Castillo_Pedro
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Ignaki Sanz makes the case that +++ AUTOANTIBODIES are integrally involved in #COVID19 immunopathogeneisis and may rise and fall w disease states- TBD what role they play in acute disease and #LongCovid @CCalabreseDO @VirusesImmunity @CleClinicMD #COVID19AB https://t.co/9dzCSh5V7R
Leonard Calabrese LCalabreseDO ( View Tweet)
"The time for young people is now! You are not the future, you are the present; you can make a difference. You may be scared, but take the opportunities and be purposeful." -Dr. A Alakija on the role of young rheumatologists in global health disparities
#ACR21 @ACRheum @yodifiji
TheDaoIndex KDAO2011 ( View Tweet)
